Zealand Pharma wants to buy access to the US market through bankrupt firm
Zealand Pharma's bid on bankrupt medtech company Valeritas is an attempt to buy a shortcut into the US market by taking over a fully functional commercial organization in the country.
When pharmaceutical company Zealand Pharma is willing to spend DKK 156 million (USD 22.8 million) on bankrupt medtech company Valeritas, it isn't because of the US company's product - rather, the company's employees and foothold in the USA.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
